The BRAIN Act aims to advance research and improve care for people living with brain tumors, directly affecting over 1 million Americans with brain tumors and their families. Key provisions include creating a searchable database of NIH-funded brain tumor biospecimens, establishing a $50 million annual research network for glioblastoma treatment, and funding a $10 million annual program for CAR-T cell therapy research. The bill also authorizes a national awareness campaign about clinical trials and biomarker testing, and creates pilot programs to develop better long-term care models for brain tumor survivors. These concrete policy changes address the lack of treatment options and stagnant survival rates for brain tumors, which have remained unchanged for 45 years.
This bill amends Chapter 11 bankruptcy rules to prevent corporate misuse of bankruptcy proceedings. It requires courts to dismiss or convert cases within 24 months of filing and establishes new grounds for dismissal, including cases that are not likely to succeed (objectively futile) or filed to delay creditors, gain tactical advantages, or cap liability for certain claims. The bill also protects specific "protected claims," such as product liability claims affecting 100+ people or claims against affiliated entities (e.g., parent companies), allowing creditors to pursue these outside the automatic bankruptcy stay. These changes apply to cases filed after the bill's enactment, aiming to ensure bankruptcy is used for reorganization, not to avoid legitimate creditor obligations.
The Agency Stability Restoration Act of 2024 amends two federal laws to clarify the timeframe for challenging agency decisions in court. It adds a 6-year statute of limitations for lawsuits under Section 702 of Title 5 (which governs judicial review of agency actions), requiring such cases to be filed within 6 years of the final agency decision. This change affects individuals, businesses, or organizations seeking to legally contest federal agency actions. The bill does not alter substantive agency powers but standardizes the deadline for judicial review under existing law.
The SAFE Act establishes a national strategy to protect fish, wildlife, and plants from climate change impacts by requiring Federal agencies to integrate climate adaptation into their conservation efforts. It mandates states to develop adaptation plans focusing on habitat protection, ecological processes, and incorporating traditional knowledge from Tribal and Native Hawaiian organizations. The Act creates a Climate Adaptation Science Center Network to provide scientific support for adaptation efforts across different regions. It requires regular review and updates of adaptation plans every four years to address changing climate conditions. This legislation directly affects Federal agencies, state governments, Tribal nations, and Native Hawaiian organizations in their conservation planning and management activities.
This bill requires lenders using the Uniform Residential Loan Application to add a specific disclaimer below the military service question: "If yes, you may qualify for a VA Home Loan. Consult your lender regarding eligibility." It directly affects military service members and veterans applying for home loans, aiming to increase awareness of VA loan eligibility. The bill mandates this change within six months of enactment and requires a GAO study within 18 months to assess whether at least 80% of lenders include the disclaimer on the form.
SRES 765 is a Senate resolution honoring the late Senator James M. Inhofe of Oklahoma following his death on July 9, 2024. The resolution commemorates his 28-year Senate service (1994-2023) and 52 years in public office, highlighting his work on defense policy, aviation legislation, infrastructure projects, and support for military bases in Oklahoma. This procedural resolution expresses the Senate's condolences and formally recognizes his legacy, rather than enacting any policy changes.
The Railroad Safety Enhancement Act of 2024 establishes new safety requirements for high-hazard trains carrying hazardous materials, including speed limits of 50 mph (40 mph in urban areas) for trains with 20 or more flammable liquid tank cars. The bill requires rail carriers to provide real-time electronic train consist information to emergency responders and State emergency commissions, including details about hazardous materials being transported, routes, and emergency response contacts. It mandates railroads to develop and regularly update hazardous materials emergency response plans, with triennial reviews by the Federal Railroad Administration. The act also phases out older tank cars by December 2027, requiring all tank cars to meet DOT-117 specifications for flammable liquids, and increases civil penalties for rail safety violations up to $5 million.
SRES 763 is a symbolic Senate resolution designating July 2024 as "Plastic Pollution Action Month." It does not create new laws or regulations but formally recognizes the environmental and health impacts of plastic pollution - citing statistics on global plastic production, low recycling rates, ocean contamination, and human microplastic exposure. The resolution encourages all U.S. individuals to voluntarily reduce plastic use, participate in cleanup efforts, and support reuse initiatives during July 2024 and year-round. It serves as a non-binding awareness tool, referencing existing public efforts like Plastics Free July and the International Coastal Cleanup. This resolution directly affects the public by promoting voluntary action, not by imposing legal requirements.
This bill authorizes Congress to award a single Congressional Gold Medal to Jens Stoltenberg, former Secretary General of NATO, recognizing his leadership during his nine-year tenure. It directs the Treasury to strike the medal and allows for the sale of bronze duplicates to cover costs. The medal honors Stoltenberg's role in strengthening NATO's defense spending, enlargement, and unity - particularly during Russia's invasion of Ukraine - though the bill itself creates no new policy or obligations. The award is purely ceremonial and affects only Stoltenberg as the recipient.
The CHOICE Act creates a new government-run health insurance plan to be offered through existing health insurance marketplaces (exchanges) starting in 2026. It requires the Secretary to establish this public option, offering bronze, silver, and gold coverage tiers with premiums set based on geographic rates and costs, and using Medicare reimbursement rates as a fallback for provider payments. The plan must comply with existing exchange rules on benefits, provider networks, and consumer protections, while collecting data to address health disparities. It is funded through premiums and a one-time start-up appropriation repaid over 10 years, with states able to form advisory councils to provide input on its operation.
S 4688, the Counter Kleptocracy Coordination Act of 2024, creates a new White House coordinator to improve federal efforts against foreign corruption and kleptocracy. The coordinator, appointed by the President from the National Security Council, will assess how foreign corruption threatens national security and coordinate anti-corruption work across agencies like State, Treasury, Justice, and USAID. Key provisions require the coordinator to align agency initiatives, brief Congress annually on progress, and collaborate with existing roles addressing foreign influence. The bill does not create new laws or funding but focuses on streamlining existing government efforts to counter corruption's links to issues like sanctions evasion and cybercrime. This is a procedural bill establishing a coordination role, not a policy change.
This bill, S 4691 (No Tax Breaks for Drug Ads Act), removes a tax deduction for pharmaceutical companies that spend on direct-to-consumer advertising of prescription drugs. It directly affects drug manufacturers by eliminating the ability to deduct expenses for ads targeting the general public through TV, radio, print, online, or social media platforms. The key provision prohibits tax deductions for all such advertising costs starting after the bill's enactment date, without changing advertising rules or banning ads. This is a concrete tax policy change affecting pharmaceutical industry spending, not a regulatory measure.
